{'52WeekChange': -0.39184952,
 'SandP52WeekChange': None,
 'address1': '9620 Medical Center Drive',
 'address2': 'Suite 300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.2,
 'askSize': 1800,
 'averageDailyVolume10Day': 828350,
 'averageVolume': 292157,
 'averageVolume10days': 828350,
 'beta': 1.033053,
 'beta3Year': None,
 'bid': 2.16,
 'bidSize': 1800,
 'bookValue': 0.697,
 'category': None,
 'circulatingSupply': None,
 'city': 'Rockville',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.985,
 'dayLow': 1.87,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.351,
 'enterpriseToRevenue': 21.765,
 'enterpriseValue': 164041776,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '301-315-2437',
 'fiftyDayAverage': 2.3837142,
 'fiftyTwoWeekHigh': 3.82,
 'fiftyTwoWeekLow': 1.15,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 46139269,
 'forwardEps': -0.31,
 'forwardPE': -6.2580647,
 'fromCurrency': None,
 'fullTimeEmployees': 125,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.46525002,
 'heldPercentInstitutions': 0.20387,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1277942400,
 'lastSplitFactor': '1:11',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/casipharmaceuticals.com',
 'longBusinessSummary': 'CASI Pharmaceuticals, Inc., a biopharmaceutical '
                        'company, develops and commercializes pharmaceutical '
                        'products and various therapeutics in China, the '
                        "United States, and internationally. The company's "
                        'product pipeline includes EVOMELA, a melphalan '
                        'hydrochloride for injection primarily for use as a '
                        'high-dose conditioning treatment prior to '
                        'hematopoietic progenitor cell transplantation in '
                        'patients with multiple myeloma. Its product pipeline '
                        'also comprise CNCT19, an autologous CD19 CAR-T '
                        'investigative product for the treatment of patients '
                        'with B-cell acute lymphoblastic leukemia (B-ALL) and '
                        'B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 '
                        'monoclonal antibody being for the treatment of '
                        'patients with multiple myeloma; ZEVALIN, a '
                        'CD20-directed radiotherapeutic antibody, to treat '
                        'patients with NHL; and Thiotepa, a chemotherapeutic '
                        'agent, which has multiple indications including use '
                        'as a conditioning treatment for use prior to '
                        'hematopoietic stem cell transplantation. In addition, '
                        'the company offers MARQIBO, a microtubule inhibitor, '
                        'approved by the FDA for the treatment of adult '
                        'patients with Philadelphia chromosome-negative ALL; '
                        'and Octreotide LAI formulations for the treatment of '
                        'acromegaly and for the control of symptoms associated '
                        'with various neuroendocrine tumours, as well as '
                        'developing a portfolio of 25 FDA-approved abbreviated '
                        'new drug applications. It has licensing agreements '
                        'with Black Belt Therapeutics Limited, Juventas Cell '
                        'Therapy Ltd., and Pharmathen Global BV. The company '
                        'was formerly known as EntreMed, Inc. and changed its '
                        'name to CASI Pharmaceuticals, Inc. in June 2014. CASI '
                        'Pharmaceuticals, Inc. was founded in 1991 and is '
                        'based in Rockville, Maryland.',
 'longName': 'CASI Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 195775104,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_354853',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -46296000,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.92,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '240-864-2600',
 'previousClose': 1.94,
 'priceHint': 4,
 'priceToBook': 2.7833571,
 'priceToSalesTrailing12Months': 25.975203,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.985,
 'regularMarketDayLow': 1.87,
 'regularMarketOpen': 1.92,
 'regularMarketPreviousClose': 1.94,
 'regularMarketPrice': 1.92,
 'regularMarketVolume': 541941,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 100915000,
 'sharesPercentSharesOut': 0.0171,
 'sharesShort': 1721763,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1753187,
 'shortName': 'CASI Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0272,
 'shortRatio': 9.36,
 'startDate': None,
 'state': 'MD',
 'strikePrice': None,
 'symbol': 'CASI',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.479,
 'twoHundredDayAverage': 2.2533092,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '5244ad8d-dd52-32c9-8a35-41a17d71c051',
 'volume': 541941,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.casipharmaceuticals.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '20850'}